Novo Nordisk locks horns with Pfizer in late bid for Metsera
While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.
deal
Bavarian Nordic’s shareholders and board in standoff amid takeover offer
BioCryst to buy Astria Therapeutics for $700m in enterprise value
Roche signs agreement to acquire 89bio in $2.4bn deal
CapVest to buy control of generics giant Stada in €10bn deal
Immedica to buy Marinus Pharmaceuticals for $151m
Investors optimistic about continued biotech and medtech IPO resurgence in 2025
AlloVir and Kalaris enter merger to advance retinal disease therapies
